














86Pretransplantation C-Peptide Level Predicts Early
PosttransplantationDiabetesMellitus andHas an Impact
on Survival after Allogeneic Stem Cell Transplantation
Michelle L. Griffith,1 Madan H. Jagasia,2 Amanda A. Misfeldt,1 Heidi Chen,3
Brian G. Engelhardt,2 Adetola Kassim,2 Bipin N. Savani,2
Margaret Survant,1 Shubhada M. Jagasia1Posttransplantation diabetes mellitus (PTDM) is a frequent complication after allogeneic stem cell transplan-
tation (allo-SCT), important for its negative impact on cardiovascular health. Risk factors for PTDM are not
well defined.We conducted a prospective study to investigate the risk factors and incidence for PTDM in the
first 100 days after allo-SCT. A total of 84 patients completed the study, 60% of whom developed PTDM. In
a multivariate logistic regression model, pretransplantation c-peptide level (.3.6 ng/mL; odds ratio [OR],
5.9; 95% confidence interval [CI], 1.77-20.22; P 5 .004), unrelated donor allo-SCT (OR, 4.3; 95% CI, 1.34-
14.2; P5 .014), and peak steroid dose.1 mg/kg/day (OR, 5.09; 95% CI, 1.19-23.2; P5 .035) were identified
as independent predictors of PTDM. In addition, overall survival (OS) was inferior in patients with PTDM
compared with those without PTDM (mean survival, 2.26 years vs 2.7 years; P 5 .021). Pretransplantation
c-peptide level greater than the cohort median (.3.6 ng/mL) also was associated with inferior OS (mean,
1.7 years vs 2.9 years; P5 .012). In a multivariate Cox proportional hazards model, high-risk disease (hazard
ratio [HR], 2.34; 95% CI, 1.09-5.28; P 5 .029) and pretransplantation c-peptide level .3.6 ng/mL (HR, 1.05;
95% CI, 1.01-1.09; P 5 .013) were independent predictors of OS when adjusted for systemic steroids and
regimen intensity. We suspect that diabetes mellitus in the immediate posttransplantation period may be
mediated via an inflammatory pathway that contributes to insulin resistance in the host adipose tissue.
Our study is the first to report the risk factors of early PTDM in patients undergoing allo-SCTand identifies
pretransplantation c-peptide as an independent predictor of diabetes and survival.
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As survival after transplantation increases, the
focus of posttransplantation care is shifting toward
avoiding long-term metabolic complications of trans-
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Compared with recipients of autologous stem cell
transplantation (SCT), recipients of allogeneic SCT
(allo-SCT) are at increased risk for posttransplantation
DM (PTDM). The reported long-term prevalence
among allo-SCT survivors ranges from 7.6% to
13.1% [3-5]. A recent retrospective cohort study
showed that 17% of mixed adult and pediatric allo-
SCT survivors developed new-onset PTDM within
the first 2 years after transplantation [6]. Allo-SCT
survivors also have an elevated long-term risk of
metabolic syndrome [7,8].
Risk factors for PTDM are not well defined.
Chronic graft-versus-host disease (GVHD) has been
associated with insulin resistance [9], but it does not
appear to be a risk factor for PTDM in all studies
[4,5]. Immunosuppressive therapy (IST) to treat
GVHD, including glucocorticoids and calcineurin
inhibitors, has been shown to promote DM [10]. Risk
factors associated with PTDM include total body
Figure 1. Study schema.
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tive prednisone doses in the first 2 years after allo-SCT
[6]. Prospective published data in this field are limited,
however.
To further elucidate risk factors for PTDM, we
conducted a prospective study of patients undergoing
allo-SCTwith calcineurin inhibitor-basedGVHDpro-
phylaxis to evaluate risk factors and incidence of new-
onset PTDM in the first 100 days posttransplantation.
We also assessed the influence of PTDM on survival.METHODS
Patient Selection and Follow-Up
Patients aged $18 years, scheduled for their first
allo-SCT, were eligible for inclusion (Figure 1). Our
institution’s Institutional Review Board approved the
study design, and all patients provided informed con-
sent. Patients who were unable to give informed con-
sent, had a positive pregnancy test, had preexisting
DM, or were unable to complete the conditioning reg-
imen before allo-SCTwere excluded. Standard institu-
tional criteria for transplantation eligibility were
applied. Baseline laboratory tests, including fasting
glucose, fasting lipid profile (total cholesterol and tri-
glycerides, with fasting low-density and high-density
lipoprotein collected for some participants), c-peptide,
and insulin, were obtained on the day before the start of
the conditioning regimen. Height, weight, and vital
signsweremeasured and recordedbefore conditioning.
The homeostatic model assessment of insulin resis-
tance (HOMA-IR) score was calculated to provide
a noninvasive estimate of insulin resistance, using the
following formula: [fasting insulin (mU/mL)  fasting
glucose (mmol/L)]/22.5 [11]. Fasting glucose levelwas measured weekly until day 100. The first fasting
glucose $126 mg/dL or random glucose $200 mg/
dL was considered diagnostic of PTDM. The forego-
ing laboratory tests and measurements were repeated
at study end, defined as development of PTDM or
day 100 after allo-SCT without the development of
PTDM. Other parameters that could influence the
development of PTDM, including indication for allo-
SCT,weight at day 100, peak systemic steroid dose, du-
ration of systemic steroid exposure until day 100, and
other IST administered, were evaluated prospectively.
All patients who survived past day 100 after allo-
SCT were followed in our long-term transplantation
clinic. Data on survival status at time of last clinical
follow-up at this institution were collected.Transplant Specifics
Most patients underwent allo-SCT with a myeloa-
blative (MA; cyclophosphamide 120 mg/kg and TBI
1200 cGy; cyclophosphamide 120 mg/kg and busulfan
16 mg/kg) or reduced-intensity (fludarabine 180 mg/
m2 and busulfan 8 mg/kg; fludarabine 90 mg/m2 and
TBI 200 cGy) regimen. GVHD prophylaxis included
calcineurin inhibitors and a short course of methotrex-
ate (MA regimen) or mycophenolate mofetil (reduced-
intensity regimen). All patients received standard
institutional care regarding antimicrobial prophylaxis,
surveillance cultures, monitoring for viral infections,
and treatment. Acute GVHD (aGVHD) was treated
in accordance with standardized institutional guide-
lines. In general, aGVHD grade II-IV was treated
with 2 mg/kg/day of prednisone equivalent for 10-14
days, followed by a taper of 10% per week. Patients
with isolated upper-gut GVHD were treated with
Table 1. Characteristics of the Study Group (n 5 84)
Variable n* Results†
Age at transplantation, years 84 46.0 (37.5-56.0)
Male sex 84 44 (52%)
Caucasian ethnicity 84 79 (94%)
Developed PTDM 84 50 (60%)
Time to PTDM, days 50 23 (14.2-33.8)
Family history of DM 84 56 (66%)
Pretransplantation BMI, kg/m2 84 27.1 (24.48-30.02)
Pretransplantation systolic blood pressure 84 119 (110-128)
Pretransplantation diastolic blood pressure 84 73 (68-80)
Hematologic diagnosis 84
Lymphoid malignancy 36 (43%)
Myeloid malignancy 36 (43%)
Other malignancy 12 (14%)
Stem cell source 84
Peripheral blood 16 (19%)







PTDM indicates posttransplantation diabetes mellitus; DM, diabetes
mellitus.
*Denominator for each variable; n <84 indicates missing values for this
variable.
†Continuous variables reported as median (IQR).
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kg/day of prednisone equivalent, followed by a taper.
Statistical Analysis
All analyses were performed using SPSS version 17
(SPSS Inc, Chicago, IL), R version 2.9.2 (R Project for
Statistical Computing, Vienna, Austria), or Stata IC
11.0 (StataCorp, College Station, TX).
Univariate analyses
To evaluate associations with PTDM, continuous
variables were compared using Wilcoxon’s rank-sum
test, and categorical variables were compared using
Pearson’s c2 test. Pearson’s c2 test was also used to
assess associations of TBI with MA conditioning and
aGVHD with TBI, MA preparative regimen, and do-
nor type. Spearman’s rank correlation was used to as-
sess relationships of c-peptide with age, baseline body
mass index (BMI), pretransplantation blood pressure,
fasting glucose concentration, triglyceride levels, and
HOMA-IR score. The cumulative incidence of
PTDM was also calculated. The Cox proportional
hazards model was used to assess the impact of age on
overall survival (OS) and the impact of PTDM as
a time-dependent variable on OS.
Multivariate analyses
Logistic regression was used for multivariate anal-
ysis of PTDM risk. C-peptide and potential confound-
ing variables were included in the logistic regression.
When there was significant correlation between two
variables, only one variable was used in the model, as
described in Results. For OS outcomes, Kaplan-
Meier survival curves for groups were calculated, and
the curves were compared using the log-rank test.
The Cox proportional hazards model was used for
multivariate survival analysis, incorporating c-peptide
and disease risk and adjusting for MA conditioning
and systemic steroid exposure. For the logistic regres-
sion and multivariate Cox proportional hazard models
involving c-peptide, the median c-peptide level of the
entire cohort (3.6 ng/mL) was selected to define
groups of high versus low c-peptide.
Outcomes
Theprimary studyendpointwas incidenceofPTDM
by day 100. Assessment of risk factors for PTDMwas the
primary aim. A secondary endpoint was OS.RESULTS
Patients
A total of 84 patients completed the study and were
included in the analysis. Baseline patient demographic
and transplant characteristics are summarized inTable 1. Demographic data, BMI, blood pressure,
and category of malignancy did not differ significantly
between the patients who went on to develop PTDM
and those who did not. No patients received steroids
as part of the conditioning regimen.Diabetes Incidence and Risk Factors
Fifty patients (60%) developed new-onset PTDM
before completing the study. The cumulative incidence
of DMwas 50% at day 41 posttransplantation and 59%
at day 98. The median time from transplantation to
diagnosis of DM was 23 days (interquartile range
[IQR], 14.2-33.8 days). Fifty-six patients (67%) were
diagnosed with aGVHD during the study period. The
grade of aGVHDdid not differ according toDM status
(Table 2). Exposure to systemic steroids at a peak dose
of .1 mg/kg/day (prednisone equivalent) was associ-
ated with PTDM (P5 .002) (Table 2).
Univariate risk factor analysis showed an increased
risk of PTDM in patients with an MA preparative
regimen, unrelated donor allo-SCT, or TBI (Table 2).
Pretransplantation c-peptide levels were higher in pa-
tients with PTDM (median, 4.45 ng/mL vs 2.6 ng/mL;
P 5 .025). The incidence of PTDM was 72.5% in pa-
tients with a pretransplantation c-peptide level above
the cohort median of 3.6 ng/mL, compared with 50%
in those with a c-peptide level#3.6 ng/mL (P5 .036).
In a multivariate logistic regression model, pre-
transplantation c-peptide level (.3.6 ng/mL; odds
ratio [OR], 5.9; 95% confidence interval [CI], 1.77-
20.22; P 5 .004), unrelated donor allo-SCT (OR, 4.3;
95% CI, 1.34-14.2; P 5 .014), and peak steroid
Table 2. Selected Factors Evaluated for PTDM
Variable n* No PTDM (n 5 33) PTDM (n 5 50) P Value
Transplant characteristics
CIBMTR disease risk 83 .771
Low 13 (39%) 16 (32%)
Intermediate 10 (30%) 16 (32%)
High 10 (30%) 18 (36%)
Unrelated donor 83 9 (27%) 31 (62%) .002
Myeloablative conditioning 83 14 (42%) 33 (66%) .034
TBI in conditioning 83 10 (30%) 26 (52%) .05
HLA mismatch 80 0 (0%) 3 (6%) .149
GVHD/treatment
Acute GVHD at study end 82 .898
Grade 0-I 13 (39%) 20 (41%)
Grade II-IV 20 (61%) 29 (59%)
Systemic steroids during the study 83 15 (45%) 28 (56%) .347
Peak steroid dose >1 mg/kg/day 43 1 (7%) 15 (54%) .002
Pretransplantation laboratory data
Fasting plasma glucose, mg/dL 82 96 (89-102)† 97.5 (92.0-105.2) .586
Fasting insulin, mU/mL 81 12.6 (7.7-22.5) 16.8 (9.73-31.15) .142
Fasting c-peptide, ng/mL 81 2.6 (2.2-4.75) 4.45 (2.90-7.42) .025
HOMA-IR 81 2.69 (1.91-5.92) 4.54 (2.59-7.19) .122
PTDM indicates posttransplantation diabetes mellitus; CIBMTR, Center for International Blood and Marrow Transplant Registry; TBI, total body
irradiation; GVHD, graft-versus-host disease; HOMA-IR, homeostatic model assessment of insulin resistance.
*Denominator for each variable; patients who died before day 100 without PTDMwere excluded. A total of 83 patients developed PTDM or survived to
day 100 without PTDM; n <83 indicates missing values for this variable.
†Continuous variables reported as median (IQR).
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P 5 .035) remained independent predictors of PTDM
(Table 3). TBIwas omitted from the logistic regression
model because of a strong association withMA prepar-
ative regimen (P\.001). aGVHD was not associated
with TBI, MA preparative regimen, or donor type,
but was associatedwith steroid use before day 100 post-
transplantation (P\.001).
Other Correlations with Pretransplantation
C-Peptide Level
Pretransplantation c-peptide level was examined as
a continuous variable for correlations with other pre-
transplantation features. It was found to be positively
correlated with increasing age (Spearman’s r 5 0.35;
P 5 .001), pretransplantation BMI (r 5 0.32;
P 5 .003), and HOMA-IR score (r 5 0.80; P\.001).
Survival Analysis
The median duration of follow-up for the study
cohort was 1.46 years (IQR, 0.6-2.1 years). EightTable 3. Multivariate Analysis for PTDM Risk
Variable OR* 95% CI P Value
Unrelated donor 4.3 1.34 -14.2 .014
Myeloablative conditioning† 3.1 0.98-9.9 .054
C-peptide >3.6 ng/mL 5.9 1.77-20.22 .004
Peak steroid dose >1 mg/kg/day 5.09 1.19-23.2 .035
PTDM indicates posttransplantation diabetes mellitus; OR, odds ratio;
CI, confidence interval.
*Logistic regression model.
†TBI was omitted from the model because of correlation with myeloa-
blative conditioning.patients were deceased at day 100, with median time
to death of 73 days (IQR, 42-80 days); 7 of these patients
had already developed PTDM, and 1 patient died of
relapse before day 100 without PTDM. Five of these
patients (63%) died of nonrelapse causes, and 3 (37%)
relapsed. Nineteen patients died after day 100, with
a median time to death of 288 days (IQR, 186-467).
Five of these patients died of relapse (26%) and 14
died of nonrelapse causes (74%). Causes of death did
not differ significantly betweenpatientswithPTDMand
those without PTDM.Median survival was not reached.
Mean survival was 2.26 years for patients with PTDM
and 2.7 years for those without DM (P5 .021). Analysis
ofPTDMasa time-dependent variable showeda signif-
icant impact of PTDMonOS (hazard ratio [HR], 3.27;
95% CI, 1.3-8.2; P 5 .01.) Higher pretransplantation
c-peptide level (.3.6 ng/mL, greater than the cohort
median) was associated with inferior OS (mean, 1.7
years vs. 2.9 years; P 5 .012) (Figure 2). Age at time
of transplantation did not significantly affect OS in
the Cox proportional hazards model (P 5 .217).
aGVHD did not affect survival status at last follow-
up. Unrelated donor status, exposure to TBI during
conditioning, use of an MA conditioning regimen,
peak steroid dose .1 mg/kg/day, and chronic GVHD
also did not influence survival status at last follow-up.
High-risk disease, as defined based on Center for
International Blood and Marrow Transplant Registry
(CIBMTR) criteria, was associatedwith inferior survival
in univariate analysis (52% of deceased patients with
high-risk disease vs 26% of living patients; P5 .04).
In a multivariate Cox proportional hazards model,
high-riskdisease (HR,2.34; 95%CI,1.09-5.28;P5 .029)
Figure 2. Kaplan-Meier survival curves according to pretransplanta-
tion c-peptide levels.
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(HR, 1.05; 95% CI, 1.01-1.09; P5 .013) were indepen-
dent predictors ofOSwhen adjusted for systemic steroids
and myeloablative conditioning (Table 4).DISCUSSION
Risk factors for PTDM remain incompletely un-
derstood. Our prospective study has identified pre-
transplantation c-peptide level not only as a risk
factor for PTDM, but also as an independent predictor
of OS. The exact association between c-peptide and
survival remains to be elucidated. It is unlikely that
this relationship is mediated via complications of
uncontrolled DM or hyperglycemia. We suspect that
c-peptide might be a surrogate marker for inflamma-
tion or the stress response to inflammation.
Our findings indicate that a higher pretransplanta-
tion c-peptide level is associated with increased risk of
new-onset PTDM, along with donor status and peak
steroid dose .1 mg/kg/day (prednisone equivalent)
in the first 100 days posttransplantation. Treatment
with steroids for aGVHD has been previously associ-
ated with PTDM. Our results validate previous obser-
vations of the association between steroids forTable 4. Multivariate Analysis of Survival
Variable HR* 95% CI P Value
CIBMTR disease risk 2.34 1.09-5.28 .029
C-peptide >3.6 ng/mL 1.05 1.01-1.09 .013
CIBMTR indicates Center for International Blood and Marrow Trans-
plant Registry; HR, hazard ratio; CI, confidence interval.
*Cox proportional hazards model adjusted for peak steroid dose >1mg/
kg/day and myeloablative conditioning.aGVHD and PTDM. Interestingly, aGVHD grade
(0-I vs II-IV) did not affect survival.
Previous studies in solid organ transplant patients
have demonstrated that high pretransplantation insu-
lin level [12], elevated random blood glucose level
[13], and impaired fasting glucose level [14] can predict
future development of PTDM. Future studies might
consider including c-peptide to examine whether the
relationship that we have demonstrated can be vali-
dated in other transplantation populations. An ele-
vated c-peptide level may reflect early insulin
resistance with a compensatory increase in endoge-
nous insulin secretion to control hyperglycemia. The
distribution of fasting insulin levels was also higher
in the group that developed PTDM, although this dif-
ference did not reach statistical significance.
Majhail et al. [6] recently explored the natural
history of PTDMand found that 17%of patients devel-
oped new-onset PTDMby 2 years posttransplantation,
with 73%of thenewcasesmanifestingwithin4weeksof
starting steroids.We foundamuchhigher prevalence in
the first 100 days posttransplantation. Our cohort had
higher BMI on average, with 73% of our patients over-
weight or obese (BMI.25), compared with 47% in the
cohort ofMajhail et al. [6]. Althoughwedidnot see a re-
lationship between increased BMI and development of
PTDM in our cohort, the predominance of overweight
and obesity within the cohort might have obscured any
such relationship. The c-peptide value of 3.6 ng/mL
represents the median in our cohort; this specific value
may not be applicable to other populations. Our study
was not designed for extensive longitudinal follow-up
or assessment of natural history beyond the first 100
days posttransplantation; thus, it is not known which
patients had remission versus persistence of diabetes
over the long-term. However, a previous report that
32%of patients withDMevident in the early posttrans-
plantation period remained diabetic at the 2-year anni-
versary [6] indicates that a significant proportion of
patients do not resolve their DM and thus remain at
increased vascular risk as a result.
A recent retrospective study found that hyperglyce-
mia, relative hypoglycemia, and increased glycemic
variability were all associated with increased nonrelapse
mortality at 200 days after allo-SCT [15]. PTDM was
significantly associated with inferior survival in our
study, and higher pretransplantation c-peptide level
was associated with inferior survival as well.
The mechanism behind the increased mortality in
PTDM is not clear. Because causes of death did not
differ significantly between the groups, it is unlikely
that hyperglycemia was a mechanism for this associa-
tion; for example, we did not see any evidence of
increased infections leading to increased mortality in
patients with PTDM. We would expect PTDM to
affect mortality several years after transplantation,
not to have an effect in the relatively short-term range
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with steroids at a peak dose .1 mg/kg/day was also
an independent predictor of PTDM suggests that
aGVHD with resulting high-dose steroid treatment
might trigger PTDM development, particularly in
those patients with underlying insulin resistance.
However, we did not see an effect of aGVHD on
survival in this analysis.
Recently, T regulatory cells (Tregs) have been
shown to be associated with improvements in inflam-
mation from adipose tissue, whereas activated conven-
tional T cells promote inflammatory markers from
adipose tissue macrophages. Insulin resistance in-
creases because of adipose tissue inflammation
[16,17]. Our group has demonstrated the importance
of Tregs at engraftment in the development of
GVHD [18]. After allo-SCT, patients withmoreTregs
may be relatively protected from an inflammatory
response in adipose tissue, whereas those with fewer
Tregs may be more prone to insulin resistance and hy-
perglycemia.Higher numbers ofTregs have been asso-
ciated with improved posttransplantation survival [19].
Under this hypothesis, patients with higher pretrans-
plantation c-peptide levels and lower numbers ofTregs
at engraftment are at the greatest risk for PTDM.
Strengths of our study include its prospective de-
sign and a priori designation of endocrine laboratory
parameters to be assessed as potential risk factors.
Limitations include a heavy predominance of Cauca-
sian patients, making the applicability of our findings
to non-Caucasian populations uncertain.
As long-term survival after allo-SCT continues to
improve, prevention and management of comorbid-
ities that affect health and quality of life is becoming
an important focus of care for an increasing number
of patients. DM is a coronary risk equivalent and also
carries a risk ofmicrovascular complications, including
renal disease, retinopathy, and neuropathy. An under-
standing of risk factors for the development of PTDM
will allow for more sophisticated pretransplantation
risk assessment and counseling for patients regarding
the risk of developing PTDM, and also might affect
monitoring after allo-SCT. Currently, international
consensus guidelines developed based on solid organ
transplantation data recommend monitoring for DM
with fasting glucose weekly for 4 weeks posttransplan-
tation and at 3, 6, and 12 months thereafter [20]; allo-
SCT patients deemed to be at high risk may needmore
frequent assessment, such as weekly to monthly, until
day 100 posttransplantation. Development of formal
guidelines for this population would aid in case finding
and introduction of appropriate therapies for glycemic
control and blood pressure control to mitigate long-
term vascular risk to the greatest degree possible.
Finally, the relationships among PTDM, pretrans-
plantation c-peptide level, and inferior survival war-
rant further investigation and validation in larger,multicenter studies. Discovering the pathophysiologic
links among these conditions might ultimately help
improve posttransplantation outcomes and survival.ACKNOWLEDGMENTS
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